Page 160 - Binder2

And perhaps most importantly:
You stop managing biologics like consumables.
And start building them like infrastructure—designed to
stay.

This is not just a better way to build one drug.
It’s a repeatable system. A foundation. A platform.

And for companies willing to lead, it’s a blueprint for
owning the next era of biologics—not with faster
approvals, but with therapies the immune system is willing
to live with.

3.10 – Case Study: COUR

Pharmaceuticals and the Rise of
Antigen-Specific Immune Tolerance

If the immune-compatible future is already being built,
COUR Pharmaceuticals is one of the clearest signs.

COUR isn’t a large-cap pharma giant or a legacy biologics
manufacturer. It’s a clinical-stage biotech quietly leading a
revolution: not in suppression, but in selective immune
education.

Their platform doesn't aim to block immune pathways. It
doesn’t use systemic immunosuppressants or checkpoint
inhibitors. Instead, it introduces antigens to the immune
system in a way that mimics how the body naturally
learns what to tolerate—using a biodegradable
nanoparticle platform designed to deliver disease-specific

158